Cagrilintide: selected references HeartPep literature library, reviewed 2026-11-16 https://heartpep.com/us/research/library/cagrilintide 1. Lau DCW, Erichsen L, Francisco AM, et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial The Lancet. DOI: https://doi.org/10.1016/S0140-6736(21)01751-7 PMID: 34798060 Source: https://pubmed.ncbi.nlm.nih.gov/34798060/ Verification: Abstract / bibliographic record. 2. Garvey WT, Blüher M, Osorto Contreras CK, et al.; REDEFINE 1 Study Group (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine. DOI: https://doi.org/10.1056/NEJMoa2502081 PMID: 40544433 Source: https://pubmed.ncbi.nlm.nih.gov/40544433/ Verification: Abstract / bibliographic record. 3. Buse JB, Bajaj HS, Dalskov SM, et al.; REIMAGINE 2 study group (2026). Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study The Lancet Diabetes & Endocrinology. DOI: https://doi.org/10.1016/S2213-8587(26)00125-7 PMID: 42251859 Source: https://pubmed.ncbi.nlm.nih.gov/42251859/ Verification: Abstract / bibliographic record. 4. The Lancet Diabetes & Endocrinology, no named author listed in PubMed (2026). Correction to Lancet Diabetes Endocrinol 2026; published online June 7. https://doi.org/10.1016/S2213-8587(26)00125-7 The Lancet Diabetes & Endocrinology. DOI: https://doi.org/10.1016/S2213-8587(26)00157-9 PMID: 42320507 Source: https://pubmed.ncbi.nlm.nih.gov/42320507/ Verification: Abstract / bibliographic record. 5. Wharton S, Broholm C, Horn D, et al. (2026). Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial The Lancet Diabetes & Endocrinology. DOI: https://doi.org/10.1016/S2213-8587(26)00275-5 PMID: 43033821 Source: https://www.sciencedirect.com/science/article/pii/S2213858726002755 Verification: Abstract / bibliographic record. These are selected background references, not evidence that a HeartPep product or batch matches a studied preparation. Cite and assess the original papers.